2022
DOI: 10.1016/j.cmi.2022.01.033
|View full text |Cite
|
Sign up to set email alerts
|

Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
24
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 40 publications
(39 citation statements)
references
References 22 publications
6
24
0
1
Order By: Relevance
“…Similarly, another retrospective cohort study conducted in Brazil reported the reduction in hospital stays and the need for mechanical ventilation in infected health care workers vaccinated with Oxford-AstraZeneca (ChAdOx1) or Corona vac [79]. Similar studies conducted elsewhere have shown the efficacy of vaccines in reducing the severity of COVID-19 and the length of hospital stay [80][81][82][83][84]. Similar to other studies, our study also shows a reduction in hospital stay by four days in fully vaccinated patients compared to unvaccinated patients indicating the efficacy of the COVISHIELD vaccine.…”
Section: Discussionmentioning
confidence: 78%
“…Similarly, another retrospective cohort study conducted in Brazil reported the reduction in hospital stays and the need for mechanical ventilation in infected health care workers vaccinated with Oxford-AstraZeneca (ChAdOx1) or Corona vac [79]. Similar studies conducted elsewhere have shown the efficacy of vaccines in reducing the severity of COVID-19 and the length of hospital stay [80][81][82][83][84]. Similar to other studies, our study also shows a reduction in hospital stay by four days in fully vaccinated patients compared to unvaccinated patients indicating the efficacy of the COVISHIELD vaccine.…”
Section: Discussionmentioning
confidence: 78%
“…14 In addition, we had the daily new death lagged for 7 days since there was suggested an interim between SARS‐CoV‐2 infection and the related death, which was estimated and averaged as 8 days. 15 , 16 The average incidence was calculated by the average daily new cases and population size. The average CFR was calculated by the average daily new death and new cases.…”
Section: Methodsmentioning
confidence: 99%
“…A total of 14 studies were included to analyze the effect of age. We found no statistical difference in the age of the two groups (SMD = 0.085, 95% CI = À0.073-0.189, p = 0.388, 12 Case-control study 346 1100 ☆☆☆ ☆☆ ☆☆ 7☆ Wi 18 Case-control study 142 20 ☆☆ ☆☆ ☆☆ 6☆ Tenforde 13 Case-control study 314 1669 ☆☆☆ ☆☆ ☆☆ 7☆ Hsu 19 Case-control study 85 85 ☆☆ ☆☆ ☆☆☆ 7☆ Blanquart 20 Case-control study 724 5459 ☆☆☆ ☆☆ ☆☆ 7☆ Bollineni 21 Case-control study 14 56 ☆ ☆☆ ☆☆☆ 6☆ Marincu 22 Case-control study 62 62 ☆☆ ☆☆ ☆☆☆ 7☆ Wolff 23 Case-control study 260 507 ☆☆☆ ☆☆ ☆☆☆ 8☆ Kalligeros 24 Case-control study 91 824 ☆☆☆ ☆☆ ☆☆☆ 8☆ Fragoulis 25 Cohort study 101 60 ☆☆☆ ☆☆ ☆☆☆ 8☆ Trunfio 26 Cohort study 55 110 ☆☆☆ ☆☆ ☆☆ 7☆ Safdar 27 Cohort study 45 65 ☆☆☆ ☆☆ ☆☆☆ 8☆ Bouton 28 Cohort study 96 329 ☆☆ ☆☆ ☆☆☆ 7☆ Bosch 29 Case-control study 126 839 ☆☆ ☆☆ ☆☆☆ 7☆ Christensen 30 Case-control study 3346 13,619 ☆☆☆ ☆☆ ☆☆☆ 8☆ Yu 31 Case-control study 23 50 ☆☆☆ ☆☆ ☆☆☆ 8☆ Bayhan 32 Case-control study 38 190 ☆☆☆ ☆☆ ☆☆☆ 8☆ Kustin 33 Case-control study 396 396 ☆☆ ☆☆ ☆☆ 6☆ Toda 34 Case-control study 11 15 ☆☆☆ ☆☆ ☆☆☆ 8☆ Tian 4 Case-control study 88 41 ☆☆☆ ☆☆ ☆☆☆ 8☆ Sayed 35 Case-control study 50 70 ☆☆☆ ☆☆ ☆☆☆ 8☆ Lee 36 Case-control study 174 587 ☆☆☆ ☆☆ ☆☆☆ 8☆ Luo 37 Case-control study 484 1782 ☆☆☆ ☆☆ ☆☆ 7☆ Puhach 38 Case-control study 139 245 ☆☆ ☆☆ ☆☆ 6☆ Whittaker 39 Case-control study 716 2487 ☆☆☆ ☆☆ ☆☆☆ 8☆ Sanghavi 40 Case-control study 149 478 ☆☆☆ ☆☆ ☆☆☆ 8☆ Butt (1) 41 Case-control study 250 250 ☆☆☆ ☆☆ ☆☆☆ 8☆ Butt (2) 42 Case-control study 456 456 ☆☆☆ ☆☆ ☆☆☆ 8☆ Spiera 43 Case-control study 88 2317 ☆☆ ☆☆ ☆☆☆ 7☆ Baltas 44 Case-control study 119 476 ☆☆☆ ☆☆ ☆☆ 7☆ John 45 Case-control study 254 508 ☆☆ ☆☆ ☆☆ 6☆ Jacobson 46 Case-control study 189 471 ☆☆ ☆☆ ☆☆ 6☆ Estofolete …”
Section: Ageunclassified